Biopharma GH Research Q2 net loss beats expectations, cash position improves

GH Research

07/08/2025 12:51

Overview

GH Research Q2 net loss beats analyst expectations, per LSEG data

Cash position improved due to $150 mln public offering in Q1 2025

R&D expenses decreased, G&A expenses increased compared to last year

Result Drivers

FDA ENGAGEMENT - Ongoing discussions with FDA regarding GH001 IND application clinical hold

COSTS DROP - R&D costs decline on drop in clinical development activities and recognition R&D tax credit, offset by higher employee expenses

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q2 EPS
-$0.15
Q2 Net Income
Beat
-$9.29 mln
-$12.90 mln (7 Analysts)
Q2 Income From Operations
Miss
-$14.70 mln
-$14.30 mln (7 Analysts)
Q2 Pretax Profit
Beat
-$9.29 mln
-$12.90 mln (7 Analysts)

Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 8 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

The average consensus recommendation for the biotechnology & medical research peer group is "buy"

Wall Street's median 12-month price target for GH Research PLC is $32.00, about 62% above its August 6 closing price of $12.15

Press Release: ID:nGNXb6yyk6

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)